February 11, 2026 02:04 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Bangladesh poll manifestos mirror India’s welfare schemes as BNP, Jamaat bet big on women, freebies | Drama ends: Pakistan makes U-turn on India boycott, to play T20 World Cup clash as per schedule | ‘Won’t allow any impediment in SIR’: Supreme Court pulls up Mamata govt over delay in sharing officers’ details | India-US trade deal: ‘Negotiations always two-way’, says Amul MD amid farmers’ concerns | Khamenei breaks 37-year-old ritual for first time amid escalating Iran-US tensions | India must push for energy independence amid global uncertainty: Vedanta chairman Anil Agarwal | Kanpur horror: Lamborghini driven by businessman’s son rams vehicles, injures six | ‘Namaste Trump beat Howdy Modi’: Congress slams PM Over India-US trade deal | Historic India-US trade pact: Tariffs cut, $500B market opportunity unlocked! | Big call from RBI: Repo rate stays at 5.25%, neutral stance continues

GVK BIO signs definitive agreement to acquire Vanta Bioscience

| | Nov 06, 2014, at 10:40 pm
Kolkata, Nov 6 (IBNS): Discovery Research and Development organization, GVK BIO, has announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai in India.

Complying with OECD GLP, ISO, USFDA GLP regulatory guidelines, the company offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. 

Vanta Bioscience also offers toxicology services using alternative methods for the Cosmetics industry.

The facility is GLP and AAALAC accredited and is armed with high-end equipment, and has infrastructure like ‘Individually ventilated Cages’ and `Intelligent Building Management’ systems.

The facility houses GLP trained scientific personnel with experience and expertise in study design and execution of regulatory directed studies leading to IND filings.

Speaking on the occasion,Manni Kantipudi, CEO, GVK BIO,said: “The acquisition is in line with our business strategy of beingan integrated drug discovery services provider for our customers. We are constantly investing in upgrading our capabilities to provide world-class R&D services. Vanta Bioscience further advances our position as we expand our service offering in GLP toxicology."

Gerard Schwickerath, Vice President and General Manager,Vanta Bioscience said:“Vanta Bioscience team is pleased that the world-class research GLP and AAALAC accredited organization will continue under the direction of GVK BIO. We are delighted to transition into an organization that can expand our offerings and provide further opportunities to our clients and staff.”

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
RBI announces repo rate cut Jun 06, 2025, at 10:51 am
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm